i2O Therapeutics develops GLP-1 combinations for cardio-renal-metabolic diseases. The company focuses on creating long-acting agonists for various targets including GLP-1r, Amylin, PYY, and Glucagon.

i2O Therapeutics

i2o Therapeutics is Boston-based company developing next generation biologic therapies

JDRF T1D Fund

Sanofi Ventures

Touchdown Ventures

Viva BioInnovator

i2o Therapeutics

i2o Therapeutics is hiring an Associate Principal/Senior Research Scientist! Come join our team and help us design formulations for novel biologics! #hiring

This Thursday, September 21, an important FDA Advisory Committee meeting granted by the Commissioner’s Office and FDA’s Chief Scientist will evaluate the data in support of ITCA 650 as a potential treatment for type 2 #diabetes. 
 
The Advisory Committee’s recommendation will be considered by The Office of the Commissioner, which will render a final decision regarding the pending New Drug Application (NDA) for ITCA 650 on behalf of the FDA in the coming months. 
 
Be sure to tune in to the public hearing this Thursday at 9am ET to see i2o present evidence supporting ITCA 650 as a safe and effective treatment for type 2 diabetes: https://bit.ly/3RsxrN4

In a recent Boston Business Journal article, Rowan Walrath spotlights #i2o and next steps for advancing our recently acquired pipeline assets and platform technology following the completion of our Series A financing and the appointment of Kurt Graves as Chairman, President and CEO.
 
Check out the article for more: bit.ly/3PhoCnG

#i2o CEO Kurt Graves sat down with Joseph Haas of Scrip to discuss his appointment as Chairman, President and CEO and highlight i2o’s recent progress, including the completion of our Series A financing and the acquisitions of proprietary pipeline assets and platform technology.
 
Check out the full article to learn the latest on i2o and how we aim to raise the standards of care in #diabetes, #obesity and related diseases with our next-generation biologics and peptides: https://lnkd.in/e8fHEyrZ

i2o Therapeutics is pleased to announce some exciting corporate updates, including the appointment of biotech industry leader Kurt Graves as Chairman, President and CEO, the successful completion of a Series A financing and the acquisitions of proprietary pipeline assets and platform technology.
 
Newly appointed CEO Kurt Graves said, “At i2o, our ultimate goal is to be an important part of the novel GLP-1 based combination products and innovative drug delivery solutions that are needed to raise the standards of care, address widespread unmet needs around poor control and poor adherence, and to help remove the barriers to access, affordability, and supply that are needed to help millions of patients.” 
 
Read the full press release to learn more about i2o’s recent progress and what’s next for the company: bit.ly/3PgOxfa

I2OB

COM:I2OBIO

i2O Therapeutics